India rejects Bayer's plea for stay against compulsory licence for Nexavar
This article was originally published in Scrip
Executive Summary
India's Intellectual Property Appellate Board (IPAB) has rejected Bayer's request for a stay against the compulsory licence granted for its anticancer Nexavar (sorafenib tosylate) to the domestic firm, Natco Pharma.